CLINICAL EVALUATION OF CEFMENOXIME (SCE-1365)
Cefmenoxime (CMX, SCE-1365), a new semisynthetic cephalosporin, was administered mainly to 10 severe infectious cases suffering from malignant neoplasms of the hematopoitic organs and its clinical usefulness was evaluated. Daily dose of cefmenoxime was 3 to 6 grams and 2 cases responded excellently,...
Saved in:
| Published in: | CHEMOTHERAPY Vol. 29; no. Supplement1; pp. 508 - 510 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | Japanese |
| Published: |
Japanese Society of Chemotherapy
25-06-1981
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Cefmenoxime (CMX, SCE-1365), a new semisynthetic cephalosporin, was administered mainly to 10 severe infectious cases suffering from malignant neoplasms of the hematopoitic organs and its clinical usefulness was evaluated. Daily dose of cefmenoxime was 3 to 6 grams and 2 cases responded excellently, 2 cases effectively and 6 cases poorly to cefmenoxime treatment showing 40% of clinical effectiveness rate. In most poor efficacy cases, Pseudomonas aeruginosa was isolated. Side effect consiered to be caused by the administration of cefmenoxime was not noticed. |
|---|---|
| ISSN: | 0009-3165 1884-5894 |
| DOI: | 10.11250/chemotherapy1953.29.Supplement1_508 |